
    
      The study included a maximum 4-week Screening Period, a maximum 7-week Titration Period for
      advanced-stage Parkinson's disease, 12-week Maintenance Period, a maximum 12-day
      De-escalation Period for advanced-stage Parkinson's Disease and 30-day Safety Follow-Up
      Period. The maximum study duration for an individual subject with advanced-stage Parkinson's
      disease was 27 weeks.
    
  